The transcriptome of CDK4/6 inhibition

Knudsen, Erik S.; Witkiewicz, Agnieszka K.

doi:10.18632/aging.101285

Cited by 1 publication

(2 citation statements)

References 8 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using The Cancer Genome Atlas (TCGA)–breast invasive carcinoma (BRCA) cohort, we determined the E2F pathway score of primary tumors as the GSVA score for the Molecular Signatures Database (MSigDb) Hallmark E2F targets gene set [ 42 ]. With median value as a cut-off, we divided the TCGA tumors into groups of low and high E2F scores.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2− Breast Cancer

Oshi

Takahashi

Tokumaru

et al. 2020

Cells

View full text Add to dashboard Buy / Rent full text

E2F transcription factors play critical roles in the cell cycle. Therefore, their activity is expected to reflect tumor aggressiveness and responsiveness to therapy. We scored 3905 tumors of nine breast cancer cohorts for this activity based on their gene expression for the Hallmark E2F targets gene set. As expected, tumors with a high score had an increased expression of cell proliferation-related genes. A high score was significantly associated with shorter patient survival, greater MKI67 expression, histological grade, stage, and genomic aberrations. Furthermore, metastatic tumors had higher E2F scores than the primary tumors from which they arose. Although tumors with a high score had greater infiltration by both pro- and anti-cancerous immune cells, they had an increased expression of immune checkpoint genes. Estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative cancer with a high E2F score achieved a significantly higher pathological complete response (pCR) rate to neoadjuvant chemotherapy. The E2F score was significantly associated with the expression of cyclin-dependent kinase (CDK)-related genes and strongly correlated with sensitivity to CDK inhibition in cell lines. In conclusion, the E2F score is a marker of breast cancer aggressiveness and predicts the responsiveness of ER-positive/HER2-negative patients to neoadjuvant chemotherapy and possibly to CDK and immune checkpoint inhibitors.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The Gene Set Variation Analysis (GSVA) method [ 41 ] was utilized to measure the E2F pathway score as the GSVA score for the E2F targets gene set of the MSigDb Hallmark collection [ 42 ] using the GSVA Bioconductor package (version 3.10). High and low E2F score designations were assigned by within-cohort median values.…”

Section: Methodsmentioning

confidence: 99%